Results for "fatigue"
Chronic Fatigue Syndrome
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex, chronic illness characterized by profound fatigue, sleep disturbances, and cognitive impairments, with post-exertional malaise being a hallmark symptom. ## Overview Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a chronic and debilitating illness that affects millions of people worldwide. Despite its prevalence, ME/CFS remains poorly understood, and its diagnosis and treatment are often shrouded in controversy. People with ME/CFS experience a wide range of symptoms, including fatigue that is not relieved by rest, sleep disturbances, memory and concentration problems, and pain. The most distinctive feature of ME/CFS is post-exertional malaise (PEM), a worsening of symptoms that can occur after even minor physical or mental activity. ME/CFS is often referred to as a "hidden" illness, as its symptoms can be subtle and may not be immediately apparent. However, the impact of ME/CFS on daily life can be profound, with many people experiencing significant limitations in their ability to work, engage in social activities, and participate in daily tasks. The exact cause of ME/CFS is still unknown, and there is no cure. However, research is ongoing to better understand the underlying mechanisms of the illness and to develop effective treatments. ## History/Background The term "chronic fatigue syndrome" (CFS) was first coined in the 1980s, although the illness itself has been described in medical literature for centuries. In the 19th century, the term "neurasthenia" was used to describe a condition characterized by fatigue, anxiety, and depression. In the 1950s and 1960s, the term "post-viral fatigue syndrome" was used to describe a condition that developed after viral infections. In the 1980s, the term "chronic fatigue syndrome" was adopted, and the illness was recognized as a distinct medical condition. In the 1990s, the term "myalgic encephalomyelitis" (ME) was reintroduced, and it is now widely used to describe the more severe form of the illness. ME/CFS is recognized as a chronic and debilitating condition by the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC). Despite its recognition as a legitimate medical condition, ME/CFS remains poorly understood, and its diagnosis and treatment are often shrouded in controversy. ## Key Information * **Prevalence:** ME/CFS affects an estimated 836,000 to 2.5 million people in the United States alone. * **Symptoms:** Fatigue that is not relieved by rest, sleep disturbances, memory and concentration problems, pain, and post-exertional malaise (PEM). * **Causes:** Unknown, but may be related to viral infections, immune system dysfunction, and genetic predisposition. * **Diagnosis:** Based on a combination of medical history, physical examination, and laboratory tests. * **Treatment:** There is no cure, but symptoms can be managed with medication, lifestyle changes, and alternative therapies. * **Prognosis:** Variable, with some people experiencing a gradual improvement in symptoms over time, while others experience a worsening of symptoms. ## Significance ME/CFS is a significant public health concern, with a profound impact on the quality of life of those affected. The illness is often misunderstood, and people with ME/CFS may experience stigma, isolation, and lack of support. Research is ongoing to better understand the underlying mechanisms of ME/CFS and to develop effective treatments. In the meantime, it is essential to raise awareness about the illness and to provide support to those affected. INFOBOX: - Name: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) - Type: Chronic and debilitating illness - Date: Recognized as a legitimate medical condition by the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) in the 1990s - Location: Affects people worldwide - Known For: Profound fatigue, sleep disturbances, memory and concentration problems, pain, and post-exertional malaise (PEM) TAGS: Chronic fatigue syndrome, myalgic encephalomyelitis, post-exertional malaise, fatigue, sleep disturbances, memory and concentration problems, pain, viral infections, immune system dysfunction, genetic predisposition, diagnosis, treatment, prognosis, public health concern, stigma, isolation, lack of support, research, awareness, support.
Health & MedicineConditions Encyclopedia Entry 1775675048
** **Rheumatoid Arthritis (RA)** is a chronic autoimmune disorder characterized by inflammation, pain, and stiffness in the joints, leading to potential long-term damage and disability. ## Overview Rheumatoid Arthritis (RA) is a complex and multifaceted condition that affects millions of people worldwide. It is a chronic autoimmune disorder, meaning that the body's immune system mistakenly attacks its own tissues, leading to inflammation and damage in the joints. RA can affect anyone, regardless of age, sex, or ethnicity, although it is more common in women and typically begins between the ages of 30 and 60. The symptoms of RA can vary widely from person to person, but often include joint pain, stiffness, swelling, and fatigue. In addition to its physical symptoms, RA can also have a significant emotional and psychological impact on those affected. Many people with RA experience anxiety, depression, and feelings of isolation and loneliness due to the chronic nature of the condition and the limitations it can impose on daily life. However, with proper treatment and management, it is possible to manage the symptoms of RA and maintain a good quality of life. ## History/Background The exact cause of RA is still not fully understood, but research suggests that it is a complex interplay of genetic, environmental, and hormonal factors. The condition has been described in medical literature for centuries, with the first recorded mention of a similar condition dating back to ancient Greece. However, it was not until the 19th century that RA was formally identified as a distinct medical condition. In the early 20th century, the discovery of the role of the immune system in RA led to the development of new treatments, including corticosteroids and disease-modifying antirheumatic drugs (DMARDs). These treatments have revolutionized the management of RA, allowing people to live longer, healthier lives with fewer symptoms. Today, RA is a major public health concern, with an estimated 1% of the global population affected. ## Key Information ### Symptoms * Joint pain and stiffness * Swelling and redness in the affected joints * Fatigue and weakness * Loss of range of motion and flexibility * Morning stiffness that lasts for more than an hour * Joint deformity and damage over time ### Diagnosis * Medical history and physical examination * Laboratory tests, including blood tests and imaging studies * Rheumatoid factor (RF) and anti-citrullinated protein antibody (anti-CCP) tests * X-rays and other imaging studies to assess joint damage ### Treatment * Medications, including DMARDs, biologics, and corticosteroids * Physical therapy and exercise to maintain joint mobility and strength * Lifestyle modifications, such as maintaining a healthy weight and avoiding smoking * Surgery to repair or replace damaged joints ## Significance Rheumatoid Arthritis is a significant public health concern due to its impact on individuals, families, and society as a whole. The condition can lead to long-term disability, reduced productivity, and increased healthcare costs. However, with proper treatment and management, it is possible to manage the symptoms of RA and maintain a good quality of life. In addition to its individual impact, RA also has significant economic and social implications. The condition is estimated to cost the global economy billions of dollars each year, and it can also have a significant impact on family relationships and social connections. INFOBOX: - **Name:** Rheumatoid Arthritis - **Type:** Chronic autoimmune disorder - **Date:** First described in ancient Greece, formally identified in the 19th century - **Location:** Worldwide - **Known For:** Chronic inflammation and damage in the joints, leading to potential long-term disability TAGS: Rheumatoid Arthritis, autoimmune disorder, chronic condition, joint pain, inflammation, fatigue, disability, treatment, management, public health concern.
Health & MedicineConditions Encyclopedia Entry 1777263788
** This encyclopedia entry is about **Rheumatoid Arthritis (RA)**, a chronic autoimmune disorder that causes inflammation and pain in the joints. **CONTENT:** ## Overview Rheumatoid Arthritis (RA) is a complex and debilitating condition that affects millions of people worldwide. It is a chronic autoimmune disorder that causes the immune system to attack the lining of the joints, leading to inflammation, pain, and stiffness. RA can affect any joint in the body, but it most commonly affects the hands, feet, wrists, elbows, knees, and ankles. The symptoms of RA can vary from person to person, but they often include joint pain and stiffness, swelling, redness, and warmth around the affected joints, as well as fatigue, fever, and loss of appetite. RA is a systemic disease, meaning that it can affect not only the joints but also other parts of the body, such as the skin, eyes, lungs, heart, and blood vessels. In severe cases, RA can lead to joint deformity, disability, and even life-threatening complications. Despite its severity, RA is a treatable condition, and with proper management, many people with RA are able to lead active and fulfilling lives. ## History/Background The first recorded description of RA dates back to the 17th century, when the English physician Thomas Sydenham described a condition that he called "gouty arthritis." However, it was not until the 20th century that RA was recognized as a distinct medical condition. In the 1940s and 1950s, researchers began to understand the role of the immune system in RA, and the development of new treatments, such as corticosteroids and disease-modifying antirheumatic drugs (DMARDs), revolutionized the management of the condition. ## Key Information RA is caused by a combination of genetic and environmental factors, including: * **Genetics:** RA tends to run in families, and certain genetic markers have been identified as risk factors for the condition. * **Environmental factors:** Exposure to certain environmental toxins, such as silica and heavy metals, has been linked to an increased risk of RA. * **Hormonal factors:** Hormonal changes, such as those that occur during pregnancy or menopause, can trigger RA in some people. The symptoms of RA can be divided into two main categories: * **Joint symptoms:** Joint pain and stiffness, swelling, redness, and warmth around the affected joints. * **Systemic symptoms:** Fatigue, fever, loss of appetite, and weight loss. RA is diagnosed based on a combination of clinical evaluation, laboratory tests, and imaging studies. The diagnosis is often made using a combination of the following criteria: * **American College of Rheumatology (ACR) criteria:** A set of criteria that includes symptoms, laboratory tests, and imaging studies to diagnose RA. * **Rheumatoid factor (RF) test:** A blood test that detects the presence of RF, an antibody that is often present in people with RA. * **C-reactive protein (CRP) test:** A blood test that measures the level of CRP, a protein that is produced in response to inflammation. ## Significance RA is a significant public health concern, affecting millions of people worldwide. It is estimated that RA affects up to 1% of the global population, and it is a leading cause of disability and work loss. RA also has a significant economic burden, with estimated annual costs of over $100 billion in the United States alone. Despite its severity, RA is a treatable condition, and with proper management, many people with RA are able to lead active and fulfilling lives. The development of new treatments, such as biologic agents and Janus kinase (JAK) inhibitors, has revolutionized the management of RA, and researchers continue to explore new treatments and therapies. **INFOBOX:** - **Name:** Rheumatoid Arthritis - **Type:** Chronic autoimmune disorder - **Date:** First described in the 17th century - **Location:** Affects joints worldwide - **Known For:** Chronic inflammation and pain in the joints **TAGS:** Rheumatoid Arthritis, autoimmune disorder, chronic condition, joint pain, inflammation, fatigue, fever, loss of appetite, disability, work loss, public health concern, economic burden, treatment, management, biologic agents, Janus kinase inhibitors.
Health & MedicineConditions Encyclopedia Entry 1775591525
** **Mitochondrial Myopathies** are a group of rare genetic disorders caused by mutations in the mitochondrial DNA, leading to muscle weakness, fatigue, and other systemic symptoms. **CONTENT:** ### Overview Mitochondrial Myopathies (MM) are a heterogeneous group of disorders characterized by the impaired function of the mitochondria, the energy-producing structures within cells. These disorders are caused by mutations in the mitochondrial DNA (mtDNA), which is inherited from one's mother. Mitochondrial myopathies affect various systems in the body, including the muscles, nervous system, and other organs. The symptoms of MM can vary widely, depending on the specific mutation and the affected individual. Mitochondrial myopathies are relatively rare, affecting approximately 1 in 5,000 to 1 in 10,000 people worldwide. However, the prevalence of MM is likely underestimated due to the lack of awareness and the complexity of diagnosing these disorders. The symptoms of MM can be subtle and may not become apparent until later in life, making diagnosis challenging. ### History/Background The first reported case of mitochondrial myopathy was in 1962, when a British neurologist, Dr. Keith Baraitser, described a patient with a rare disorder characterized by muscle weakness, fatigue, and other systemic symptoms. Since then, numerous cases have been reported, and the understanding of MM has evolved significantly. In the 1980s, the discovery of the mitochondrial DNA and the development of techniques to analyze mtDNA mutations led to a better understanding of the genetic basis of MM. ### Key Information Mitochondrial myopathies are caused by mutations in the mitochondrial DNA, which can occur in any of the 37 genes that code for proteins involved in energy production. The most common mutations associated with MM include: * **MELAS syndrome**: a condition characterized by muscle weakness, seizures, and other systemic symptoms. * **MERRF syndrome**: a condition characterized by muscle weakness, ataxia, and other systemic symptoms. * **KSS syndrome**: a condition characterized by muscle weakness, hearing loss, and other systemic symptoms. The symptoms of MM can vary widely, depending on the specific mutation and the affected individual. Common symptoms include: * **Muscle weakness**: weakness and wasting of muscles, particularly in the face, arms, and legs. * **Fatigue**: persistent and debilitating fatigue, even after rest. * **Headaches**: frequent and severe headaches. * **Seizures**: seizures and other neurological symptoms. * **Vision problems**: blurred vision, double vision, and other vision problems. ### Significance Mitochondrial myopathies are significant because they highlight the importance of mitochondrial function in maintaining overall health. The symptoms of MM can have a profound impact on an individual's quality of life, making it essential to diagnose and manage these disorders effectively. While there is no cure for MM, various treatments can help manage symptoms and improve quality of life. **INFOBOX:** - Name: Mitochondrial Myopathies - Type: Genetic disorder - Date: 1962 (first reported case) - Location: Worldwide - Known For: Rare genetic disorders caused by mitochondrial DNA mutations **TAGS:** Mitochondrial myopathies, genetic disorders, muscle weakness, fatigue, seizures, headaches, vision problems, mitochondrial DNA, mtDNA mutations.
Health & MedicineConditions Encyclopedia Entry 1775850427
Mitochondrial myopathies are a group of rare genetic disorders that affect the mitochondria, the energy-producing structures within muscle cells, leading to muscle weakness, fatigue, and other systemic symptoms.
Health & MedicineConditions Encyclopedia Entry 1775523183
** This encyclopedia entry is about **Mitochondrial Myopathies**, a group of rare genetic disorders affecting the mitochondria, the energy-producing structures within cells. **CONTENT:** ## Overview Mitochondrial myopathies are a group of rare genetic disorders that affect the mitochondria, the energy-producing structures within cells. These disorders are caused by mutations in the mitochondrial DNA, which leads to impaired energy production and cellular dysfunction. Mitochondrial myopathies can affect various parts of the body, including the muscles, nervous system, and other organs. The symptoms and severity of the disorders can vary widely among individuals, and they often manifest in childhood or adolescence. Mitochondrial myopathies are characterized by a range of symptoms, including muscle weakness, fatigue, and pain. Some individuals may experience seizures, loss of coordination, and vision problems. In severe cases, the disorders can lead to life-threatening complications, such as respiratory failure and cardiac arrest. The disorders are often inherited in an autosomal dominant or maternal pattern, meaning that a single copy of the mutated gene is sufficient to cause the condition. ## History/Background The first reported cases of mitochondrial myopathies date back to the 1960s, when researchers identified a group of patients with muscle weakness and other symptoms that were linked to mitochondrial dysfunction. Since then, numerous studies have been conducted to understand the genetic and molecular mechanisms underlying these disorders. In 1988, the first mitochondrial DNA mutation was identified as the cause of a mitochondrial myopathy. Since then, over 1,000 different mutations have been identified, and the disorders have been classified into several subtypes. ## Key Information Mitochondrial myopathies are caused by mutations in the mitochondrial DNA, which affects the production of energy in the form of ATP. The disorders can be classified into several subtypes, including: - **NARP syndrome** (Neuropathy, Ataxia, and Retinitis Pigmentosa): a rare disorder characterized by muscle weakness, vision loss, and ataxia. - **MELAS syndrome** (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes): a disorder characterized by muscle weakness, seizures, and stroke-like episodes. - **Kearns-Sayre syndrome**: a disorder characterized by muscle weakness, vision loss, and cardiac problems. ## Significance Mitochondrial myopathies are significant because they highlight the importance of mitochondrial function in maintaining cellular health. The disorders also underscore the importance of genetic testing and counseling for individuals and families affected by these conditions. Furthermore, research on mitochondrial myopathies has led to a greater understanding of the molecular mechanisms underlying these disorders and has paved the way for the development of new treatments. **INFOBOX:** - **Name:** Mitochondrial Myopathies - **Type:** Genetic Disorders - **Date:** First reported cases in the 1960s - **Location:** Worldwide - **Known For:** Rare genetic disorders affecting mitochondrial function **TAGS:** Mitochondrial myopathies, genetic disorders, mitochondrial DNA, energy production, muscle weakness, fatigue, seizures, vision problems, NARP syndrome, MELAS syndrome, Kearns-Sayre syndrome, genetic testing, counseling. **When to Seek Professional Care:** If you or a family member is experiencing symptoms of mitochondrial myopathies, seek medical attention from a qualified healthcare professional. Early diagnosis and treatment can significantly improve outcomes and quality of life.
Health & MedicineFibromyalgia
** Fibromyalgia is a chronic, multisystem disorder marked by widespread musculoskeletal pain together with fatigue, cognitive difficulties, and a constellation of other symptoms that significantly impair quality of life. **CONTENT:** ## Overview Fibromyalgia (often abbreviated **FM**) is a long‑term health condition characterized primarily by **widespread chronic pain** that persists for at least three months and is felt on both sides of the body, above and below the waist. In addition to pain, individuals with FM commonly report **fatigue**, **unrefreshing sleep**, **cognitive disturbances** (sometimes called “fibro‑fog”), **headaches**, **depression**, and **abdominal cramping**. Current diagnostic criteria (the 2016 revisions of the American College of Rheumatology guidelines) require that patients not only meet a pain‑distribution threshold but also score above a set severity level on at least **one** of six associated symptom domains: fatigue, cognitive impairment, unrefreshed sleep, abdominal pain, depression, or headache. The condition is **non‑progressive**—it does not worsen structurally over time—but symptoms can fluctuate, with periods of relative remission alternating with flare‑ups. Because the **cause of fibromyalgia remains unknown**, it is classified as a **central sensitization syndrome**: the nervous system appears to amplify pain signals, and normal sensory inputs may be perceived as painful. This neurobiological model helps explain why patients often experience heightened sensitivity to temperature, pressure, and even light. Importantly, fibromyalgia is **not** a disease of the joints, muscles, or connective tissue; imaging and laboratory tests typically appear normal, which can lead to misdiagnosis or dismissal of symptoms. Early recognition and a multidisciplinary treatment plan—combining medication, physical therapy, cognitive‑behavioral strategies, and lifestyle modifications—are essential for improving function and reducing suffering. **If you experience persistent, widespread pain accompanied by the above symptoms, seek evaluation from a qualified health professional** such as a rheumatologist, primary‑care physician, or pain specialist. ## History/Background The term “fibromyalgia” was first coined in the **1970s**, merging the Greek words *fibro* (fibrous tissue) and *myalgia* (muscle pain). Early descriptions, however, date back to the 19th century when physicians noted “muscular rheumatism” in patients, especially women, who presented with diffuse pain without clear inflammatory markers. In **1990**, the American College of Rheumatology (ACR) introduced the first formal classification criteria, focusing on **tender point examination**—the presence of pain at 11 of 18 specific sites. This approach dominated research for two decades but was criticized for its subjectivity and exclusion of many patients whose pain patterns did not fit the tender‑point model. A major shift occurred in **2010** when the ACR released revised criteria that emphasized **symptom severity** and **widespread pain index**, allowing for a more inclusive diagnosis. Further refinements in **2016** added the requirement of at least one additional symptom domain (fatigue, cognition, sleep, etc.) to capture the syndrome’s multidimensional nature. Throughout the 2000s, advances in functional MRI and neurochemical studies revealed abnormal pain processing pathways, supporting the central sensitization hypothesis and moving fibromyalgia from a “psychogenic” label toward a recognized neurobiological disorder. ## Key Information - **Epidemiology:** Fibromyalgia affects **2–4 %** of the global population, with a striking female predominance (approximately 80–90 % of diagnosed cases). Onset most commonly occurs between ages **30–55**, though it can appear at any age, including adolescence. - **Diagnostic Criteria:** The 2016 ACR guidelines require (1) a **Widespread Pain Index (WPI) ≥ 7** or **WPI ≥ 4** plus a **Symptom Severity Scale (SSS) ≥ 5**, and (2) the presence of **≥ 1** of the six associated symptoms above a severity threshold. Symptoms must be present for at least **three months** and not be better explained by another medical condition. - **Pathophysiology Theories:** Proposed mechanisms include (a) **central sensitization** with heightened dorsal horn excitability, (b) dysregulation of **neurotransmitters** such as serotonin, norepinephrine, and substance‑P, (c) **hypothalamic‑pituitary‑adrenal (HPA) axis** dysfunction leading to abnormal stress responses, and (d) **genetic predisposition**—family studies suggest a heritable component. No single theory fully accounts for all clinical features. - **Treatment Options:** No cure exists, but a combination of **pharmacologic** (e.g., duloxetine, milnacipran, pregabalin), **non‑pharmacologic** (graded exercise, aerobic conditioning, tai chi, yoga), and **psychological** interventions (cognitive‑behavioral therapy, mindfulness) can reduce symptom burden. Patient education and self‑management strategies are critical. - **Comorbidities:** FM frequently co‑occurs with **irritable bowel syndrome, chronic fatigue syndrome, migraine, temporomandibular joint disorder, and mood disorders**. Recognizing these overlaps helps clinicians tailor comprehensive care plans. ## Significance Fibromyalgia matters because it represents a **major source of disability** worldwide, accounting for millions of lost workdays and substantial health‑care expenditures. Its **subjective nature** challenges clinicians, leading to delayed diagnosis—average time from symptom onset to diagnosis can exceed **5 years**. This delay exacerbates functional decline and psychological distress. By acknowledging fibromyalgia as a legitimate, biologically based condition, the medical community reduces stigma, encourages research funding, and improves access to multidisciplinary treatment. Moreover, insights gained from studying central sensitization have broader implications for other chronic pain syndromes, potentially guiding novel analgesic development and informing public health strategies aimed at **pain management** and **mental‑health integration**. Patients, families, and health‑care systems benefit when fibromyalgia is recognized early, managed holistically, and supported with evidence‑based interventions. If you or someone you know struggles with the hallmark symptoms, **prompt professional evaluation** is essential to rule out other conditions, obtain an accurate diagnosis, and begin an individualized treatment plan. **INFOBOX:** - **Name:** Fibromyalgia - **Type:** Chronic multisystem pain syndrome / Central sensitization disorder - **Date:** First formal diagnostic criteria published 1990 (ACR); current criteria 2016 - **Location:** Global (affects individuals worldwide) - **Known For:** Widespread chronic pain combined with fatigue, cognitive impairment, and sleep disturbances **TAGS:** chronic pain, central sensitization, rheumatology, fatigue, cognitive dysfunction, multidisciplinary treatment, diagnostic criteria, quality of life
Health & MedicineConditions Encyclopedia Entry 1776146412
Mitochondrial myopathies are a group of rare genetic disorders affecting the mitochondria, leading to muscle weakness, fatigue, and other systemic symptoms.
Health & MedicineConditions Encyclopedia Entry 1776302950
Fibromyalgia is a chronic condition characterized by widespread musculoskeletal pain, fatigue, and cognitive difficulties, affecting millions of people worldwide.
Health & MedicineConditions Encyclopedia Entry 1776352624
Mitochondrial myopathies are a group of rare genetic disorders that affect the mitochondria, the energy-producing structures within cells, leading to muscle weakness, fatigue, and other systemic symptoms. ## Overview Mitochondrial myopathies are a diverse group of disorders caused by mutations in the mitochondrial DNA (mtDNA) or nuclear DNA (nDNA) that affect the function of the mitochondria. These organelles are responsible for generating energy for the cell through the process of oxidative phosphorylation. In mitochondrial myopathies, the mitochondria are unable to produce sufficient energy, leading to a range of symptoms, including muscle weakness, fatigue, and other systemic problems. The disorders can be inherited in an autosomal dominant, autosomal recessive, or maternal pattern, depending on the specific mutation. Mitochondrial myopathies can affect various systems in the body, including the nervous system, heart, and muscles. The symptoms can vary widely depending on the specific disorder and the individual affected. Some common symptoms include muscle weakness, fatigue, exercise intolerance, and muscle pain. In severe cases, mitochondrial myopathies can lead to life-threatening complications, such as cardiac failure, respiratory failure, and seizures. ## History/Background The first descriptions of mitochondrial myopathies date back to the 1960s, when a group of researchers discovered a link between certain muscle disorders and mitochondrial dysfunction. Since then, numerous studies have shed light on the genetic and molecular mechanisms underlying these disorders. In the 1980s, the discovery of mtDNA mutations led to a greater understanding of the role of mitochondrial DNA in the development of these disorders. Today, mitochondrial myopathies are recognized as a distinct group of disorders, with over 150 different mutations identified. ## Key Information Mitochondrial myopathies can be classified into several subtypes, including: * **Kearns-Sayre syndrome**: a rare disorder characterized by progressive external ophthalmoplegia, pigmentary retinopathy, and cardiac conduction abnormalities. * **Myoclonic epilepsy with ragged-red fibers (MERRF)**: a disorder characterized by myoclonic seizures, ataxia, and muscle weakness. * **NARP syndrome**: a disorder characterized by neuropathy, ataxia, and retinitis pigmentosa. * **Leigh syndrome**: a disorder characterized by subacute necrotizing encephalomyelopathy, with symptoms including seizures, ataxia, and muscle weakness. Other key facts about mitochondrial myopathies include: * **Inheritance**: Mitochondrial myopathies can be inherited in an autosomal dominant, autosomal recessive, or maternal pattern. * **Prevalence**: The disorders are rare, affecting approximately 1 in 5,000 to 1 in 10,000 individuals. * **Symptoms**: Symptoms can vary widely, including muscle weakness, fatigue, exercise intolerance, and muscle pain. * **Treatment**: There is no cure for mitochondrial myopathies, but various treatments can help manage symptoms and slow disease progression. ## Significance Mitochondrial myopathies are significant because they highlight the importance of mitochondrial function in maintaining cellular health. The disorders also underscore the importance of genetic testing and counseling in identifying individuals at risk. Furthermore, research into mitochondrial myopathies has led to a greater understanding of the molecular mechanisms underlying these disorders, which has implications for the development of new treatments for other diseases. INFOBOX: - Name: Mitochondrial Myopathies - Type: Rare genetic disorders - Date: First described in the 1960s - Location: Global - Known For: Affecting mitochondrial function and leading to muscle weakness, fatigue, and other systemic symptoms TAGS: Mitochondrial myopathies, genetic disorders, muscle weakness, fatigue, exercise intolerance, muscle pain, Kearns-Sayre syndrome, MERRF, NARP syndrome, Leigh syndrome, mitochondrial DNA, nuclear DNA, oxidative phosphorylation.
Health & MedicineConditions Encyclopedia Entry 1776988325
** **Mitochondrial Myopathies** are a group of rare genetic disorders affecting the mitochondria, the energy-producing structures within cells, leading to muscle weakness and other systemic symptoms. ## Overview Mitochondrial Myopathies (MMs) are a diverse group of disorders characterized by the impaired function of the mitochondria, the powerhouses of cells responsible for generating energy in the form of ATP (adenosine triphosphate). These conditions are caused by mutations in the mitochondrial DNA (mtDNA), which is separate from the DNA found in the cell's nucleus. Mitochondrial myopathies can affect various tissues and organs, including muscles, the nervous system, and the heart. The symptoms of MMs can vary widely among individuals, but common manifestations include muscle weakness, fatigue, and other systemic symptoms. The diagnosis of mitochondrial myopathies can be challenging due to the complexity of the underlying genetic mutations and the overlapping symptoms with other conditions. However, advances in genetic testing and molecular biology have improved the accuracy of diagnosis and the development of targeted therapies. While there is currently no cure for mitochondrial myopathies, various treatments can help manage symptoms and improve quality of life. ## History/Background The first descriptions of mitochondrial myopathies date back to the 1960s, when researchers identified a group of patients with muscle weakness and other systemic symptoms. However, it wasn't until the 1980s that the genetic basis of these conditions was understood, with the discovery of mutations in the mitochondrial DNA. Since then, numerous studies have elucidated the molecular mechanisms underlying mitochondrial myopathies and identified several subtypes of the condition. Key dates in the history of mitochondrial myopathies include: * 1960s: First descriptions of mitochondrial myopathies * 1980s: Discovery of mutations in mitochondrial DNA * 1990s: Identification of several subtypes of mitochondrial myopathies * 2000s: Development of genetic testing and molecular biology techniques for diagnosis and treatment ## Key Information Mitochondrial myopathies are a heterogeneous group of disorders, with several subtypes characterized by distinct genetic mutations and clinical manifestations. Some of the most common subtypes include: * **Kearns-Sayre Syndrome (KSS)**: A rare condition caused by a deletion in the mitochondrial DNA, characterized by muscle weakness, heart block, and other systemic symptoms. * **Myoclonic Epilepsy with Ragged-Red Fibers (MERRF)**: A condition caused by a point mutation in the mitochondrial DNA, characterized by muscle weakness, seizures, and other systemic symptoms. * **Leigh Syndrome**: A condition caused by a mutation in the mitochondrial DNA, characterized by muscle weakness, seizures, and other systemic symptoms. ## Significance Mitochondrial myopathies are a significant cause of morbidity and mortality worldwide, affecting individuals of all ages and backgrounds. While the diagnosis and treatment of these conditions have improved significantly in recent years, there is still much to be learned about the underlying molecular mechanisms and the development of effective therapies. The study of mitochondrial myopathies has also shed light on the importance of mitochondrial function in human health and disease. Mitochondrial dysfunction has been implicated in a wide range of conditions, including neurodegenerative diseases, cancer, and metabolic disorders. INFOBOX: - **Name:** Mitochondrial Myopathies - **Type:** Genetic disorder - **Date:** 1960s (first descriptions) - **Location:** Worldwide - **Known For:** Rare genetic disorders affecting mitochondrial function TAGS: Mitochondrial myopathies, genetic disorders, mitochondrial DNA, muscle weakness, fatigue, Kearns-Sayre Syndrome, Myoclonic Epilepsy with Ragged-Red Fibers, Leigh Syndrome, mitochondrial function, genetic testing, molecular biology.
Health & MedicineConditions Encyclopedia Entry 1775298066
Mitochondrial myopathies are a group of rare genetic disorders that affect the mitochondria, the energy-producing structures within cells, leading to muscle weakness, fatigue, and other systemic symptoms.
Health & MedicineConditions Encyclopedia Entry 1775350927
** **Mitochondrial Myopathies** are a group of rare genetic disorders affecting the mitochondria, the energy-producing structures within cells, leading to muscle weakness and other systemic symptoms. **CONTENT:** ### Overview Mitochondrial myopathies are a group of rare genetic disorders caused by mutations in the mitochondrial DNA. These disorders affect the mitochondria, the energy-producing structures within cells, leading to impaired energy production and various systemic symptoms. Mitochondrial myopathies can affect any part of the body, but they often manifest as muscle weakness, fatigue, and other neurological symptoms. The disorders are typically inherited in an autosomal dominant or maternal pattern, meaning they can be passed down from a parent or inherited from a mother. Mitochondrial myopathies are often classified into several subtypes, including Kearns-Sayre syndrome, MELAS syndrome, and myoclonic epilepsy with ragged-red fibers (MERRF). Each subtype has distinct clinical features and symptoms, but they all share a common underlying cause: impaired energy production in the mitochondria. The disorders can be challenging to diagnose, as the symptoms can be nonspecific and may resemble those of other conditions. ### History/Background The first reported case of mitochondrial myopathy was in 1957, when a British neurologist named John Walton described a patient with a rare condition characterized by muscle weakness, fatigue, and other neurological symptoms. However, it wasn't until the 1980s that the genetic basis of mitochondrial myopathies was discovered. Researchers identified mutations in the mitochondrial DNA as the underlying cause of the disorders, leading to a greater understanding of the molecular mechanisms involved. ### Key Information Mitochondrial myopathies are caused by mutations in the mitochondrial DNA, which is separate from the nuclear DNA found in the cell's nucleus. The mutations can occur in any of the 37 genes found in the mitochondrial DNA, leading to impaired energy production in the mitochondria. The disorders can affect any part of the body, but they often manifest as muscle weakness, fatigue, and other neurological symptoms. The symptoms of mitochondrial myopathies can vary widely depending on the subtype and individual affected. Common symptoms include: * Muscle weakness and fatigue * Neurological symptoms, such as seizures, tremors, and ataxia * Vision loss and hearing loss * Cardiac problems, such as arrhythmias and cardiomyopathy * Gastrointestinal problems, such as diarrhea and abdominal pain ### Significance Mitochondrial myopathies are rare disorders, but they have significant implications for individuals and families affected. The disorders can have a profound impact on quality of life, leading to disability and premature death. However, advances in genetic testing and molecular diagnosis have improved the accuracy and speed of diagnosis, allowing for earlier intervention and treatment. Research into mitochondrial myopathies has also led to a greater understanding of the molecular mechanisms involved in energy production and the role of mitochondria in human disease. This knowledge has implications for the development of new treatments and therapies for a range of conditions, including cancer, neurodegenerative diseases, and metabolic disorders. **INFOBOX:** - Name: Mitochondrial Myopathies - Type: Rare genetic disorders - Date: First reported case in 1957 - Location: Worldwide - Known For: Impaired energy production in the mitochondria leading to muscle weakness and other systemic symptoms **TAGS:** Mitochondrial myopathies, Kearns-Sayre syndrome, MELAS syndrome, MERRF, mitochondrial DNA, genetic disorders, muscle weakness, fatigue, neurological symptoms, rare diseases. **When to Seek Professional Care:** If you or a family member is experiencing symptoms that may be related to mitochondrial myopathies, seek medical attention from a qualified healthcare professional. Early diagnosis and treatment can improve outcomes and quality of life.
Health & MedicineConditions Encyclopedia Entry 1776913205
Mitochondrial myopathies are a group of rare genetic disorders that affect the mitochondria, the energy-producing structures within cells, leading to muscle weakness, fatigue, and other systemic symptoms.
Health & MedicineConditions Encyclopedia Entry 1776460513
** **Mitochondrial Myopathies** are a group of rare genetic disorders characterized by the progressive degeneration of muscle tissue due to mutations in the mitochondrial DNA. **CONTENT:** ## Overview Mitochondrial myopathies are a collection of rare genetic disorders that affect the mitochondria, the energy-producing structures within cells. These disorders are caused by mutations in the mitochondrial DNA, which is separate from the DNA found in the cell's nucleus. Mitochondrial myopathies are characterized by the progressive degeneration of muscle tissue, leading to muscle weakness, fatigue, and other systemic symptoms. The disorders are typically inherited in a maternal lineage, as only egg cells contribute mitochondrial DNA to the developing fetus. Mitochondrial myopathies can affect various systems in the body, including the nervous system, heart, and gastrointestinal system. The symptoms and severity of the disorders can vary widely among affected individuals, making diagnosis and treatment challenging. While there is no cure for mitochondrial myopathies, various treatments and management strategies can help alleviate symptoms and improve quality of life. ## History/Background The first reported cases of mitochondrial myopathies date back to the 1960s, when researchers identified a group of patients with progressive external ophthalmoplegia (PEO), a condition characterized by weakness and paralysis of the eye muscles. In the 1980s, researchers discovered that PEO was caused by mutations in the mitochondrial DNA. Since then, numerous other mitochondrial myopathies have been identified, including Kearns-Sayre syndrome, MELAS syndrome, and myoclonic epilepsy with ragged-red fibers (MERRF). ## Key Information Mitochondrial myopathies are caused by mutations in the mitochondrial DNA, which can be inherited from a mother or occur spontaneously. The disorders are characterized by the following key features: * **Muscle weakness and fatigue**: Affected individuals experience progressive muscle weakness and fatigue, particularly in the muscles of the face, arms, and legs. * **Muscle degeneration**: Muscle tissue degenerates, leading to muscle wasting and weakness. * **Systemic symptoms**: Mitochondrial myopathies can affect various systems in the body, including the nervous system, heart, and gastrointestinal system. * **Inheritance**: Mitochondrial myopathies are typically inherited in a maternal lineage. ## Significance Mitochondrial myopathies are significant because they highlight the importance of mitochondrial function in maintaining cellular health. The disorders also underscore the need for early diagnosis and treatment to prevent long-term damage and improve quality of life. While there is no cure for mitochondrial myopathies, various treatments and management strategies can help alleviate symptoms and slow disease progression. **INFOBOX:** - **Name:** Mitochondrial Myopathies - **Type:** Genetic disorder - **Date:** 1960s (first reported cases) - **Location:** Worldwide - **Known For:** Progressive degeneration of muscle tissue due to mutations in mitochondrial DNA **TAGS:** Mitochondrial myopathies, genetic disorders, muscle degeneration, mitochondrial DNA, Kearns-Sayre syndrome, MELAS syndrome, MERRF, PEO, muscle weakness, fatigue, systemic symptoms, inheritance, maternal lineage. **Important Note:** If you or a family member is experiencing symptoms of mitochondrial myopathies, seek medical attention from a qualified healthcare professional. Early diagnosis and treatment can significantly improve outcomes and quality of life.
Health & MedicineConditions Encyclopedia Entry 1777230006
Mitochondrial myopathies are a group of rare genetic disorders affecting the mitochondria, leading to muscle weakness, fatigue, and other systemic symptoms.
Health & MedicineConditions Encyclopedia Entry 1775250906
Mitochondrial myopathies are a group of rare genetic disorders affecting muscle function, caused by mutations in the mitochondrial DNA.
Health & MedicineConditions Encyclopedia Entry 1776840725
** This encyclopedia entry is about **Mitochondrial Myopathies**, a group of rare genetic disorders that affect the mitochondria, the energy-producing structures within cells. **CONTENT:** ### Overview Mitochondrial myopathies are a group of rare genetic disorders that affect the mitochondria, the energy-producing structures within cells. These disorders are caused by mutations in the mitochondrial DNA, which is separate from the DNA found in the cell's nucleus. Mitochondrial myopathies can affect various parts of the body, including the muscles, brain, and other organs. The symptoms of these disorders can vary widely, but they often include muscle weakness, fatigue, and other systemic problems. Mitochondrial myopathies are often inherited in a matrilineal pattern, meaning that they are passed down from mother to child. This is because only egg cells contribute mitochondria to the fertilized egg, while sperm cells do not. As a result, mitochondrial myopathies are more common in women, who can pass the disorder to their children. There are several different types of mitochondrial myopathies, each with its own unique set of symptoms and characteristics. Some of the most common types include Kearns-Sayre syndrome, MELAS syndrome, and NARP syndrome. Each of these disorders has its own distinct set of symptoms and requires a specific treatment approach. ### History/Background The study of mitochondrial myopathies began in the 1960s, when researchers first discovered that some patients with muscle weakness and other systemic problems had abnormal mitochondria. In the 1970s and 1980s, researchers made significant progress in understanding the genetic basis of these disorders, including the discovery of the first mitochondrial DNA mutations. One of the key milestones in the study of mitochondrial myopathies was the development of techniques for analyzing mitochondrial DNA. This allowed researchers to identify the specific mutations that cause these disorders and to develop new treatments. ### Key Information Mitochondrial myopathies are caused by mutations in the mitochondrial DNA, which is responsible for producing the energy that cells need to function. These mutations can affect various parts of the body, including the muscles, brain, and other organs. Some of the key symptoms of mitochondrial myopathies include: * Muscle weakness and fatigue * Systemic problems, such as heart disease and diabetes * Vision and hearing loss * Seizures and other neurological problems * Developmental delays and intellectual disability There are several different types of mitochondrial myopathies, each with its own unique set of symptoms and characteristics. Some of the most common types include: * Kearns-Sayre syndrome: This is a rare disorder that affects the muscles, heart, and other organs. It is characterized by muscle weakness, fatigue, and other systemic problems. * MELAS syndrome: This is a rare disorder that affects the muscles, brain, and other organs. It is characterized by muscle weakness, fatigue, seizures, and other neurological problems. * NARP syndrome: This is a rare disorder that affects the muscles, brain, and other organs. It is characterized by muscle weakness, fatigue, seizures, and other neurological problems. ### Significance Mitochondrial myopathies are a group of rare genetic disorders that affect the mitochondria, the energy-producing structures within cells. These disorders are caused by mutations in the mitochondrial DNA and can affect various parts of the body, including the muscles, brain, and other organs. The study of mitochondrial myopathies has significant implications for our understanding of the genetic basis of disease and the development of new treatments. By studying these disorders, researchers have gained a better understanding of the role of mitochondria in energy production and have developed new techniques for analyzing mitochondrial DNA. **INFOBOX:** - Name: Mitochondrial Myopathies - Type: Genetic disorder - Date: 1960s (first discovered) - Location: Worldwide - Known For: Rare genetic disorders affecting the mitochondria **TAGS:** Mitochondrial myopathies, genetic disorders, mitochondrial DNA, Kearns-Sayre syndrome, MELAS syndrome, NARP syndrome, muscle weakness, fatigue, systemic problems.
Health & MedicineConditions Encyclopedia Entry 1776815413
** **Mitochondrial Myopathies** are a group of rare genetic disorders that affect the mitochondria, the energy-producing structures within cells, leading to muscle weakness, fatigue, and other systemic symptoms. ## Overview Mitochondrial Myopathies (MM) are a diverse group of disorders caused by mutations in the mitochondrial DNA, which is responsible for producing energy for the cell. These conditions affect the mitochondria's ability to produce adenosine triphosphate (ATP), the primary energy source for muscle cells. As a result, patients with MM experience muscle weakness, fatigue, and other systemic symptoms. Mitochondrial Myopathies are often inherited in an autosomal dominant or maternal pattern, meaning that a single copy of the mutated gene is enough to cause the condition, and it is passed down from mother to child. Mitochondrial Myopathies are characterized by a range of symptoms, including muscle weakness, particularly in the proximal muscles (those closest to the trunk of the body), exercise intolerance, and fatigue. Some patients may also experience other systemic symptoms, such as cardiac conduction defects, hearing loss, and visual disturbances. The severity and progression of the condition can vary widely among individuals, and some patients may experience a gradual decline in muscle function over time. ## History/Background The first reported case of a mitochondrial myopathy was in 1962 by Dr. Hans Eiberg, a Danish physician who described a family with a rare disorder characterized by muscle weakness and exercise intolerance. Since then, numerous cases have been reported, and the condition has been recognized as a distinct entity within the field of neuromuscular disorders. In the 1980s, the discovery of the mitochondrial DNA and its role in energy production led to a greater understanding of the underlying mechanisms of MM. ## Key Information Mitochondrial Myopathies are caused by mutations in the mitochondrial DNA, which can be inherited or acquired. The most common mutations associated with MM are in the mtDNA genes that encode for the respiratory chain complexes, particularly complex I, III, and IV. These mutations can lead to a reduction in ATP production, resulting in muscle weakness and fatigue. There are several types of Mitochondrial Myopathies, including: * **Kearns-Sayre Syndrome (KSS)**: a rare disorder characterized by muscle weakness, exercise intolerance, and cardiac conduction defects. * **Myoclonic Epilepsy with Ragged-Red Fibers (MERRF)**: a disorder characterized by muscle weakness, seizures, and ragged-red fibers (a hallmark of mitochondrial myopathies). * **Neuropathy, Ataxia, and Retinitis Pigmentosa (NARP)**: a rare disorder characterized by muscle weakness, ataxia, and visual disturbances. ## Significance Mitochondrial Myopathies are a significant cause of muscle weakness and fatigue, particularly in young adults. Early diagnosis and treatment can help manage symptoms and improve quality of life. However, there is currently no cure for MM, and treatment is focused on managing symptoms and preventing complications. ## InfoBox: - **Name:** Mitochondrial Myopathies - **Type:** Genetic disorder - **Date:** 1962 (first reported case) - **Location:** Worldwide - **Known For:** Muscle weakness, fatigue, and other systemic symptoms ## Tags: Mitochondrial myopathies, genetic disorder, muscle weakness, fatigue, Kearns-Sayre syndrome, MERRF, NARP, mitochondrial DNA, respiratory chain complexes, ATP production. **Important Note:** If you or someone you know is experiencing symptoms of Mitochondrial Myopathies, it is essential to seek medical attention from a qualified healthcare professional. Early diagnosis and treatment can help manage symptoms and improve quality of life.
Health & MedicineConditions Encyclopedia Entry 1775387525
** This entry is about **Mitochondrial Myopathies**, a group of rare genetic disorders affecting the mitochondria, the energy-producing structures within cells. **CONTENT:** ### Overview Mitochondrial Myopathies (MMs) are a group of rare genetic disorders caused by mutations in the mitochondrial DNA. These disorders affect the mitochondria, the energy-producing structures within cells, leading to muscle weakness, fatigue, and other systemic symptoms. MMs are characterized by their unique inheritance pattern, as they are passed down from mother to child through the mitochondria. This condition is often associated with **mitochondrial dysfunction**, which can lead to a range of symptoms, including muscle pain, weakness, and fatigue. Mitochondrial Myopathies are a complex group of disorders, with over 150 different mutations identified in the mitochondrial DNA. The symptoms of MMs can vary widely, depending on the specific mutation and the individual affected. Some people may experience mild symptoms, while others may have more severe symptoms that affect their daily lives. In some cases, MMs can lead to life-threatening complications, such as heart failure or respiratory failure. ### History/Background The first descriptions of MMs date back to the 1960s, when researchers began to identify cases of mitochondrial myopathies in families. However, it wasn't until the 1980s that the genetic basis of these disorders was understood. In 1988, a team of researchers identified the first mitochondrial DNA mutation associated with a mitochondrial myopathy. Since then, numerous studies have been conducted to better understand the genetics and pathophysiology of MMs. ### Key Information * **Prevalence:** Mitochondrial Myopathies are rare, affecting approximately 1 in 5,000 people worldwide. * **Inheritance:** MMs are inherited in a maternal lineage, meaning they are passed down from mother to child through the mitochondria. * **Symptoms:** Symptoms of MMs can include muscle weakness, fatigue, muscle pain, and other systemic symptoms. * **Diagnosis:** Diagnosis of MMs typically involves a combination of genetic testing, muscle biopsy, and imaging studies. * **Treatment:** There is currently no cure for MMs, but treatment options are available to manage symptoms and improve quality of life. ### Significance Mitochondrial Myopathies are significant because they highlight the importance of mitochondrial function in maintaining overall health. MMs also underscore the need for further research into the genetics and pathophysiology of these disorders. Additionally, MMs have significant implications for families affected by these disorders, as they can have a profound impact on quality of life and family dynamics. **INFOBOX:** - **Name:** Mitochondrial Myopathies - **Type:** Rare genetic disorder - **Date:** First described in the 1960s - **Location:** Worldwide - **Known For:** Unique inheritance pattern and mitochondrial dysfunction **TAGS:** Mitochondrial dysfunction, genetic disorder, rare disease, muscle weakness, fatigue, muscle pain, mitochondrial DNA, maternal inheritance, genetic testing, muscle biopsy, imaging studies, treatment options, quality of life, family dynamics. **When to Seek Professional Care:** If you or a family member is experiencing symptoms of Mitochondrial Myopathies, it is essential to seek medical attention from a qualified healthcare professional. Early diagnosis and treatment can significantly improve quality of life and manage symptoms. If you have a family history of MMs or are concerned about your risk, consult with a genetic counselor or a healthcare professional for guidance.